B. Riley restated their hold rating on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note released on Tuesday. The brokerage currently has a $16.00 target price on the specialty pharmaceutical company’s stock. B. Riley also issued estimates for AMAG Pharmaceuticals’ FY2022 earnings at $1.78 EPS.

A number of other research analysts have also recently issued reports on the stock. ValuEngine raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, January 3rd. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, November 8th. Jefferies Group reaffirmed a buy rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Morgan Stanley dropped their target price on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an overweight rating for the company in a report on Friday, November 3rd. Finally, Janney Montgomery Scott reaffirmed a hold rating on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. Twelve analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $21.27.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.30 during midday trading on Tuesday, reaching $13.95. 959,742 shares of the company traded hands, compared to its average volume of 827,891. The stock has a market capitalization of $492.27, a PE ratio of -2.29 and a beta of 0.79. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.20. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. equities research analysts predict that AMAG Pharmaceuticals will post -4.17 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the company. Hartford Investment Management Co. acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $186,000. Cubist Systematic Strategies LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. 361 Capital LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Aperio Group LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $198,000. Finally, Municipal Employees Retirement System of Michigan grew its position in shares of AMAG Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 4,870 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2018/01/17/amag-pharmaceuticals-amag-earns-hold-rating-from-b-riley.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.